DB-GuideNCT07683754
T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Start date pushed from Sep 18, 2026 to Nov 4, 2026
- Study sites: 5 to 6
Notable Recruitment opened Show 4 more changesShow less
- Eligibility criteria expanded, about 27 words
- Trial sites expanded: 0 → 5 locations
- Start date changed from estimate of Sep 4, 2026 to Sep 18, 2026
- Secondary endpoints: details revised at 9 of 18 entries
- Notable Eligibility criteria shortened, about 14 wordsv2
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Progression-free Survival (PFS) Rate at 24 Months
Timeframe: From start of Upfront Treatment phase until disease progression (PD) or death, whichever occurs first, up to approximately 24 months
Secondary (15)
Progression-free Survival (PFS) Rate at 12 Months
Objective Response Rate
Progression-free Survival (PFS) Rate From Start of Maintenance Treatment at 12 Months
Overall Survival at 24 Months
Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESI), and Death
Show 10 moreShow less
Time to First AESI and TEAE
Change From Maintenance Treatment Baseline in EORTC-QLQC30 Global Health Score, Functional, and Symptom Scales.
Change From Maintenance Treatment Baseline in EQ-5D-5L Overall Score
Change From Maintenance Treatment Baseline in EQ-5D-5L Dimension-specific Scores
Change From Maintenance Treatment Baseline in EQ-VAS
Time to Deterioration/Improvement After the Transition to Maintenance Treatment Phase
Change From Upfront Treatment Baseline in EORTC-QLQC30 Global Health Score, Functional, Symptom Scales.
Change From Upfront Treatment Baseline in EQ-5D-5L Overall Score
Change From Upfront Treatment Baseline in EQ-5D-5L Dimension-specific Scores
Change From Upfront Treatment Baseline in EQ-VAS
Arms and interventions
T-DXdExperimental
Adult participants with previously untreated advanced or metastatic HER2+/HR+ breast cancer who will receive T-DXd intravenously every 3 weeks (IV Q3W) in 3 treatment phases: Upfront treatment phase: T-DXd + pertuzumab IV Q3W Maintenance treatment phase: Trastuzumab + palbociclib + endocrine therapy + pertuzumab IV Q3W T-DXD retreatment phase: T-DXd monotherapy IV Q3W
Drugs: Trastuzumab deruxtecan, Trastuzumab, Pertuzumab, Endocrine Therapy, Palbociclib
Sites
6 sites in 1 country